Corneal endothelium

EyeYon Medical Receives CE Mark for its EndoArt® Implant to Treat Chronic Corneal Edema

Retrieved on: 
Tuesday, June 8, 2021
Medicine, Clinical medicine, Medical specialties, Ophthalmology, Cornea, Eye surgery, Endothelium, Implant, Corneal endothelium, Corneal opacity

This unique implant enables doctors to treat endothelial-related chronic corneal edema with a minimally invasive surgery that erodes the use of human tissue.

Key Points: 
  • This unique implant enables doctors to treat endothelial-related chronic corneal edema with a minimally invasive surgery that erodes the use of human tissue.
  • The EndoArt is designed to replace dysfunctional endothelium in patients awaiting human donor tissue as a first-line treatment for patients with chronic corneal edema.
  • "We are proud to receive CE mark for our unique EndoArt implant which is set to transform the way patients with chronic corneal edema are treated," said Nahum Ferera, Co-Founder and CEO of EyeYon Medical.
  • EyeYon Medical's flagship product is an Artificial Endothelial Layer - EndoArt, a synthetic implant, attached to the posterior corneal surface to treat chronic corneal edema secondary to endothelial dysfunction.

EyeYon Medical Raises $25 million in Series C to Transform Corneal Care

Retrieved on: 
Monday, March 15, 2021
Medical specialties, Clinical medicine, Eye surgery, Medicine, Corneal transplantation, Cornea, Contact lens, Corneal endothelium, Effects of long-term contact lens wear on the cornea

With nearly 13 million patients on the waiting list for corneal transplant, the EndoArt was created in an effort to ease global shortages of corneal donations.

Key Points: 
  • With nearly 13 million patients on the waiting list for corneal transplant, the EndoArt was created in an effort to ease global shortages of corneal donations.
  • The latest investments position EyeYon Medical as a global pioneer in the ophthalmology space and in corneal care."
  • EyeYon Medical's flagship product is an Artificial Endothelial Layer - EndoArt, a synthetic implant, attached to the posterior corneal surface to treat chronic corneal edema secondary to endothelial dysfunction.
  • EyeYon Medical also developed the Hyper CL, an FDA approved unique contact lens that acts as a premium therapeutic contact lens for a variety of corneal conditions which require eye drop treatment.

Artificial Cornea and Corneal Implant Market by Type, Transplant Type, Disease Indication and End-users - Global Forecast to 2026

Retrieved on: 
Friday, February 26, 2021
Medical specialties, Clinical medicine, Medicine, Eye surgery, Ophthalmology, Corneal transplantation, Cornea, Keratoprosthesis, Corneal opacity, Corneal endothelium

DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Artificial Cornea and Corneal Implant Market by Type (Human Cornea, Artificial Cornea), Transplant Type (Penetrating Keratoplasty, Endothelial Keratoplasty), Disease Indication, End Users (Hospitals, Specialty Clinics & ASCs) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Artificial Cornea and Corneal Implant Market by Type (Human Cornea, Artificial Cornea), Transplant Type (Penetrating Keratoplasty, Endothelial Keratoplasty), Disease Indication, End Users (Hospitals, Specialty Clinics & ASCs) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • Human cornea segment accounted for the largest share of artificial cornea and corneal implant market in 2020.
  • On the basis of type, the artificial cornea and corneal implants market is segmented into the human cornea and artificial cornea.
  • In 2020, the human cornea segment accounted for the largest share of the artificial cornea and corneal implants market.

Artificial Cornea and Corneal Implant Market worth $599 million by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, February 10, 2021
Clinical medicine, Medical specialties, Medicine, Ophthalmology, Eye surgery, Corneal transplantation, Fuchs' dystrophy, Keratoprosthesis, Cornea, Corneal opacity, Corneal endothelium

On the basis of type, the artificial cornea and corneal implants market is segmented into human cornea and artificial cornea.

Key Points: 
  • On the basis of type, the artificial cornea and corneal implants market is segmented into human cornea and artificial cornea.
  • Penetrating keratoplasty segment accounted for the largest share of artificial cornea and corneal implant market in 2020.
  • In 2020, the penetrating keratoplasty segment accounted for the largest share of the global artificial cornea and corneal implants market.
  • In 2020, the Fuchs' dystrophy segment accounted for the largest share of artificial cornea and corneal implant market.

Artificial Cornea and Corneal Implant Market worth $599 million by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, February 10, 2021
Clinical medicine, Medical specialties, Medicine, Ophthalmology, Eye surgery, Corneal transplantation, Fuchs' dystrophy, Keratoprosthesis, Cornea, Corneal opacity, Corneal endothelium

On the basis of type, the artificial cornea and corneal implants market is segmented into human cornea and artificial cornea.

Key Points: 
  • On the basis of type, the artificial cornea and corneal implants market is segmented into human cornea and artificial cornea.
  • Penetrating keratoplasty segment accounted for the largest share of artificial cornea and corneal implant market in 2020.
  • In 2020, the penetrating keratoplasty segment accounted for the largest share of the global artificial cornea and corneal implants market.
  • In 2020, the Fuchs' dystrophy segment accounted for the largest share of artificial cornea and corneal implant market.

Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophy

Retrieved on: 
Tuesday, February 9, 2021
Seniors, Biotechnology, Pharmaceutical, Optical, Surgery, Health, Consumer, Clinical trials, Ophthalmology, Anatomy, Medical specialties, Angiology, Endothelium, Cornea, Eye surgery, Fuchs' dystrophy, Corneal endothelium, FECD and corneal endothelial disorders, TTHX1114, Trefoil Therapeutics

Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy (FECD).

Key Points: 
  • Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy (FECD).
  • The multi-center clinical trial is an open label study involving 40 or more patients already scheduled for DSO surgery.
  • Endpoints being assessed in the study include endothelial recovery, corneal edema & clearing and visual acuity improvement after DSO surgery.
  • TTHX1114 has been shown in preclinical studies to stimulate endothelial cell proliferation and migration, and drive regeneration of the corneal endothelial layer.

Konan Medical Introduces CellChek20™, the Next Generation Specular Microscope

Retrieved on: 
Wednesday, September 30, 2020
Anatomy, Ophthalmology, Corneal endothelium, Visual system, Konan, Cornea, Eye bank, Microscopy

Specular microscopy from Konan Medical is widely regarded as the Gold Standard for cellular imaging and analytic assessment of the corneal endothelium.

Key Points: 
  • Specular microscopy from Konan Medical is widely regarded as the Gold Standard for cellular imaging and analytic assessment of the corneal endothelium.
  • Konan Medical USA CEO Charles Stewart added, "CellChek 20 has immediately generated a rebound in sales from customers and distributors.
  • Konan Medical is a pioneer in specular microscopy devices since 1979 and is mentioned in FDA panel minutes as being the "gold standard".
  • Headquartered in Irvine, California, Konan Medical USA Inc. develops specialized diagnostic products for eye care clinicians and eye banks.

Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies

Retrieved on: 
Wednesday, August 19, 2020
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Anatomy, Clinical medicine, Medicine, Ophthalmology, Eye surgery, Corneal endothelium, Visual system, Corneal transplantation, Cornea, Corneal dystrophies in dogs, Corneal opacity

Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy.

Key Points: 
  • Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy.
  • TTHX1114 has demonstrated in multiple preclinical models the ability to stimulate corneal endothelial cell proliferation and drive the regeneration and healing of the corneal endothelium.
  • Fuchs Endothelial Corneal Dystrophy is the leading cause of corneal transplantation in the U.S. Corneal transplant is currently the only treatment option for many people with CED.
  • The INTREPID trial is a prospective, multi-center randomized, masked, placebo-controlled, study involving up to 71 patients with moderate to severe corneal endothelial dystrophy.

The Global Corneal Implants Market is expected to grow from USD 376.03 Million in 2019 to USD 798.30 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 13.36%

Retrieved on: 
Tuesday, June 9, 2020
Medicine, Medical specialties, Clinical medicine, Eye surgery, Corneal transplantation, Cornea, Implant, Corneal endothelium, Legacy Devers Eye Institute

On the basis of Transplant Type, the Corneal Implants Market is studied across Anterior Lmellar Keratoplasty, Endothelial Lamellar Keratoplasty, and Penetrating Keratoplasty.

Key Points: 
  • On the basis of Transplant Type, the Corneal Implants Market is studied across Anterior Lmellar Keratoplasty, Endothelial Lamellar Keratoplasty, and Penetrating Keratoplasty.
  • On the basis of End User, the Corneal Implants Market is studied across Ambulatory Surgical Centers, Eye Clinics, and Hospitals.
  • On the basis of Geography, the Corneal Implants Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • What are the modes and strategic moves considered suitable for entering the Global Corneal Implants Market?